We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Chemicon and Axordia to Co-Develop Antibody Markers

Chemicon and Axordia to Co-Develop Antibody Markers

Chemicon and Axordia to Co-Develop Antibody Markers

Chemicon and Axordia to Co-Develop Antibody Markers

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Chemicon and Axordia to Co-Develop Antibody Markers "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Serologicals Corporation has announced that Chemicon International, Inc., its wholly-owned subsidiary, and Axordia Ltd. have signed an exclusive agreement to co-develop antibody markers from Axordia's proprietary human embryonic stem (ES) cell lines.

Under the terms of this agreement, Axordia will contribute proprietary expertise and materials for antibody generation and antibody characterization and Chemicon will commercialize the antibody research tools arising from this collaboration.

Through this agreement, Chemicon will be able to supply antibody markers to the worldwide ES cell research community.

“Chemicon is pleased to be entering into this exclusive collaborative agreement with Axordia, and its world class scientists, in the stem cell marker field,” said Jeffrey D. Linton, President of Chemicon.

“This Agreement will allow us to expand our successful portfolio of stem cell antibody reagents.”

“New antibodies resulting from this exclusive collaboration will increase the inventive process already being provided by Chemicon to thousands of human ES cell researchers worldwide.”

“In addition, we look forward to furthering our collaboration with Axordia to co-develop and market additional innovative human ES cell products,” stated Mr. Linton.

“Axordia believes that antibodies along with other key discovery technologies will be crucial in enabling stem cells to deliver their full potential to palliate and cure some of the most debilitating diseases,” said Dr. V. Paul Gerskowitch, CEO of Axordia. 

“Our partnership with a market leader in research and drug discovery tools represents a powerful step in bringing this potential forward and is recognition of our world class expertise in developing the tools needed to make the promise of stem cell technology a reality.”